Korean Journal of Radiology

  • 제24권12호
  • /
  • Pages.1249-1259
  • /
  • 2023
  • /
  • 1229-6929(pISSN)
  • /
  • 2005-8330(eISSN)
대한영상의학회 (The Korean Society of Radiology)
권호 표지
DOI QR코드

DOI QR Code

Clinical Outcomes and Cost-Effectiveness of Osteoporosis Screening With Dual-Energy X-ray Absorptiometry

  • Chiao-Lin Hsu (Health Management Center, Kaohsiung Veterans General Hospital) ;
  • Pin-Chieh Wu (Health Management Center, Kaohsiung Veterans General Hospital) ;
  • Chun-Hao Yin (Department of Medical Education and Research, Kaohsiung Veterans General Hospital) ;
  • Chung-Hwan Chen (Department of Orthopaedics and Orthopaedic Research Center, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University) ;
  • King-Teh Lee (Department of Healthcare Administration and Medical Informatics, College of Health Science, Kaohsiung Medical University) ;
  • Chih-Lung Lin (Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital) ;
  • Hon-Yi Shi (Department of Healthcare Administration and Medical Informatics, College of Health Science, Kaohsiung Medical University)
  • 투고 : 2023.06.16
  • 심사 : 2023.09.15
  • 발행 : 2023.12.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: This study aimed to evaluate the clinical outcomes and cost-effectiveness of dual-energy X-ray absorptiometry (DXA) for osteoporosis screening. Materials and Methods: Eligible patients who had and had not undergone DXA screening were identified from among those aged 50 years or older at Kaohsiung Veterans General Hospital, Taiwan. Age, sex, screening year (index year), and Charlson comorbidity index of the DXA and non-DXA groups were matched using inverse probability of treatment weighting (IPTW) for propensity score analysis. For cost-effectiveness analysis, a societal perspective, 1-year cycle length, 20-year time horizon, and discount rate of 2% per year for both effectiveness and costs were adopted in the incremental cost-effectiveness (ICER) model. Results: The outcome analysis included 10337 patients (female:male, 63.8%:36.2%) who were screened for osteoporosis in southern Taiwan between January 1, 2012, and December 31, 2021. The DXA group had significantly better outcomes than the non-DXA group in terms of fragility fractures (7.6% vs. 12.5%, P < 0.001) and mortality (0.6% vs. 4.3%, P < 0.001). The DXA screening strategy gained an ICER of US$ -2794 per quality-adjusted life year (QALY) relative to the non-DXA at the willingness-to-pay threshold of US$ 33004 (Taiwan's per capita gross domestic product). The ICER after stratifying by ages of 50-59, 60-69, 70-79, and ≥ 80 years were US$ -17815, US$ -26862, US$ -28981, and US$ -34816 per QALY, respectively. Conclusion: Using DXA to screen adults aged 50 years or older for osteoporosis resulted in a reduced incidence of fragility fractures, lower mortality rate, and reduced total costs. Screening for osteoporosis is a cost-saving strategy and its effectiveness increases with age. However, caution is needed when generalizing these cost-effectiveness results to all older populations because the study population consisted mainly of women.

키워드

과제정보

This work was supported by grants through funding from the Ministry of Science and Technology (MOST 108-2410-H-037-006-SS3 & MOST 111-2410-H-037-002-MY3) and Kaohsiung Veterans General Hospital (KSVGH 112-132).

참고문헌

  1. Mueller D, Weyler E, Gandjour A. Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis. Pharmacoeconomics 2008;26:513-536
  2. Shepstone L, Lenaghan E, Cooper C, Clarke S, Fong-Soe-Khioe R, Fordham R, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet 2018;391:741-747
  3. Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, Orwoll ES, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 2007;298:629-637
  4. Ito K. Cost-effectiveness of screening for osteoporosis in older men with a history of falls. JAMA Netw Open 2020;3:e2027584
  5. Yoshimura M, Moriwaki K, Noto S, Takiguchi T. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women. Osteoporos Int 2017;28:643-652
  6. Nayak S, Roberts MS, Greenspan SL. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med 2011;155:751-761
  7. Turner DA, Khioe RFS, Shepstone L, Lenaghan E, Cooper C, Gittoes N, et al. The cost-effectiveness of screening in the community to reduce osteoporotic fractures in older women in the UK: economic evaluation of the SCOOP study. J Bone Miner Res 2018;33:845-851
  8. Chan DC, McCloskey EV, Chang CB, Lin KP, Lim LC, Tsai KS, et al. Establishing and evaluating FRAX(R) probability thresholds in Taiwan. J Formos Med Assoc 2017;116:161-168
  9. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press, 2015
  10. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083-3107
  11. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015;34:3661-3679
  12. Schacht A, Bogaerts K, Bluhmki E, Lesaffre E. A new nonparametric approach for baseline covariate adjustment for two-group comparative studies. Biometrics 2008;64:1110-1116
  13. Federspiel JJ, Anstrom KJ, Xian Y, McCoy LA, Effron MB, Faries DE, et al. Comparing inverse probability of treatment weighting and instrumental variable methods for the evaluation of adenosine diphosphate receptor inhibitors after percutaneous coronary intervention. JAMA Cardiol 2016;1:655-665
  14. Hong GS, Lee CW, Lee JH, Kim B, Lee JB. Clinical impact of a quality improvement program including dedicated emergency radiology personnel on emergency surgical management: a propensity score-matching study. Korean J Radiol 2022;23:878-888
  15. Wang CY, Fu SH, Hung CC, Yang RS, Lin JW, Chen HM, et al. Impact of the requirement of bone mineral density evidence on utilization of anti-osteoporosis medications, clinical outcome and medical expenditures of patient with hip fracture in Taiwan. Int J Health Policy Manag 2022;11:470-478
  16. Abrahamsen B, Osmond C, Cooper C. Life expectancy in patients treated for osteoporosis: observational cohort study using national Danish prescription data. J Bone Miner Res 2015;30:1553-1559
  17. Bliuc D, Tran T, van Geel T, Adachi JD, Berger C, van den Bergh J, et al. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study. Osteoporos Int 2019;30:817-828
  18. Chen JL, Tai TW, Chou CY, Ku CK, Chien LN, Huang TW, et al. Incidence of different types of subsequent fractures and related mortality in Taiwan. Arch Osteoporos 2022;17:55
  19. Soong YK, Tsai KS, Huang HY, Yang RS, Chen JF, Wu PC, et al. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int 2013;24:511-521
  20. Guzon-Illescas O, Perez Fernandez E, Crespi Villarias N, Quiros Donate FJ, Pena M, Alonso-Blas C, et al. Mortality after osteoporotic hip fracture: incidence, trends, and associated factors. J Orthop Surg Res 2019;14:203
  21. Lee TC, Ho PS, Lin HT, Ho ML, Huang HT, Chang JK. One-year readmission risk and mortality after hip fracture surgery: a national population-based study in Taiwan. Aging Dis 2017;8:402-409
  22. Ministry of Health and Welfare. Analysis of statistical results of death causes in 2020 Taiwan (R.O.C.), 2019 [accessed on June 16, 2023]. Available at: https://www.mohw.gov.tw/np-126-2.html
  23. World Health Organization. World health statistics 2021: monitoring health for the SDGs, sustainable development goals [accessed on May 20, 2021]. Available at: https://www.who.int/publications/i/item/9789240027053
  24. Ho-Le TP, Tran TS, Bliuc D, Pham HM, Frost SA, Center JR, et al. Epidemiological transition to mortality and refracture following an initial fracture. Elife 2021;10:e61142
  25. Mobley LR, Hoerger TJ, Wittenborn JS, Galuska DA, Rao JK. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making 2006;26:194-206
  26. Si L, Winzenberg TM, Chen M, Jiang Q, Neil A, Palmer AJ. Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study. Osteoporos Int 2016;27:2259-2269
  27. Su Y, Lai FTT, Yip BHK, Leung JCS, Kwok TCY. Cost-effectiveness of osteoporosis screening strategies for hip fracture prevention in older Chinese people: a decision tree modeling study in the Mr. OS and Ms. OS cohort in Hong Kong. Osteoporos Int 2018;29:1793-1805
  28. Merlijn T, Swart KM, van Schoor NM, Heymans MW, van der Zwaard BC, van der Heijden AA, et al. The effect of a screening and treatment program for the prevention of fractures in older women: a randomized pragmatic trial. J Bone Miner Res 2019;34:1993-2000
  29. Cornelissen D, de Kunder S, Si L, Reginster JY, Evers S, Boonen A, et al. Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. Osteoporos Int 2020;31:1645-1669
  30. Pisu M, Kopperdahl DL, Lewis CE, Saag KG, Keaveny TM. Cost-effectiveness of osteoporosis screening using biomechanical computed tomography for patients with a previous abdominal CT. J Bone Miner Res 2019;34:1229-1239
  31. Song YS, Lee WW, Park MS, Kim NT, Sung KH. Usefulness of bone SPECT/CT for predicting avascular necrosis of the femoral head in children with slipped capital femoral epiphysis or femoral neck fracture. Korean J Radiol 2022;23:264-270
  32. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005
  33. Lee HY, Hung MC, Hu FC, Chang YY, Hsieh CL, Wang JD. Estimating quality weights for EQ-5D (EuroQol-5 dimensions) health states with the time trade-off method in Taiwan. J Formos Med Assoc 2013;112:699-706
  34. Kung AW, Fan T, Xu L, Xia WB, Park IH, Kim HS, et al. Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study. BMC Womens Health 2013;13:7
  35. Soreskog E, Borgstrom F, Shepstone L, Clarke S, Cooper C, Harvey I, et al. Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study. Osteoporos Int 2020;31:1499-1506
  36. Ramachandran S, Williams SA, Weiss RJ, Wang Y, Zhang Y, Nsiah I, et al. Gender disparities in osteoporosis screening and management among older adults. Adv Ther 2021;38:3872-3887